Clinical presentation, management, and pathophysiology of neuropathic itch
Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropat...
Gespeichert in:
Veröffentlicht in: | Lancet neurology 2018-08, Vol.17 (8), p.709-720 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 720 |
---|---|
container_issue | 8 |
container_start_page | 709 |
container_title | Lancet neurology |
container_volume | 17 |
creator | Steinhoff, Martin Schmelz, Martin Szabó, Imre Lőrinc Oaklander, Anne Louise |
description | Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch. |
doi_str_mv | 10.1016/S1474-4422(18)30217-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2074122058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442218302175</els_id><sourcerecordid>2071125403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq0KVGDbn1AUiQuVNtTjj8S3Cq1aCkLiQHu2vPaENUrsYCeV9t-T7G459MJpRq-e-dBDyBegV0Ch-vYIohalEIxdgvrKKYO6lB_I6SGu5NFbz9gJOcv5mU6QUPCRnHBKOacVnJK7VeuDt6Yt-oQZw2AGH8Oy6EwwT9hNwbIwwRW9GTax32yzj2182haxKQKOKc65t4Uf7OYTOW5Mm_HzoS7In58_fq9-lfcPN7er6_vSCiWHkivHxVphbdHYdaUUGCebxjDFKK6BOuOUwqbhYGvHlKA1rytQVNJGSImKL8jlfm-f4suIedCdzxbb1gSMY9aM1gIYo3JGL_5Dn-OYwvTdTAEwKSYRCyL3lE0x54SN7pPvTNpqoHqWrXey9WxSg9I72VpOc-eH7eO6Q_c29c_uBHzfAzjp-Osx6Ww9BovOJ7SDdtG_c-IVIUqNwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2071125403</pqid></control><display><type>article</type><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</creator><creatorcontrib>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</creatorcontrib><description>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(18)30217-5</identifier><identifier>PMID: 30033061</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical trials ; Cytokines ; Dermatology ; Diabetes mellitus ; Diabetic neuropathy ; Diagnosis ; Disease Management ; Drugs ; Gastrin ; Herpes zoster ; Humans ; Multiple sclerosis ; Mutation ; Narcotics ; Nervous system ; Neuralgia - diagnosis ; Neuralgia - physiopathology ; Neuralgia - therapy ; Neurokinin ; Neurokinin NK1 receptors ; Peripheral neuropathy ; Polyneuropathy ; Pruritus ; Pruritus - diagnosis ; Pruritus - physiopathology ; Pruritus - therapy ; Skin ; Ulcers</subject><ispartof>Lancet neurology, 2018-08, Vol.17 (8), p.709-720</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</citedby><cites>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1474442218302175$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30033061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steinhoff, Martin</creatorcontrib><creatorcontrib>Schmelz, Martin</creatorcontrib><creatorcontrib>Szabó, Imre Lőrinc</creatorcontrib><creatorcontrib>Oaklander, Anne Louise</creatorcontrib><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</description><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Dermatology</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathy</subject><subject>Diagnosis</subject><subject>Disease Management</subject><subject>Drugs</subject><subject>Gastrin</subject><subject>Herpes zoster</subject><subject>Humans</subject><subject>Multiple sclerosis</subject><subject>Mutation</subject><subject>Narcotics</subject><subject>Nervous system</subject><subject>Neuralgia - diagnosis</subject><subject>Neuralgia - physiopathology</subject><subject>Neuralgia - therapy</subject><subject>Neurokinin</subject><subject>Neurokinin NK1 receptors</subject><subject>Peripheral neuropathy</subject><subject>Polyneuropathy</subject><subject>Pruritus</subject><subject>Pruritus - diagnosis</subject><subject>Pruritus - physiopathology</subject><subject>Pruritus - therapy</subject><subject>Skin</subject><subject>Ulcers</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE1P3DAQhq0KVGDbn1AUiQuVNtTjj8S3Cq1aCkLiQHu2vPaENUrsYCeV9t-T7G459MJpRq-e-dBDyBegV0Ch-vYIohalEIxdgvrKKYO6lB_I6SGu5NFbz9gJOcv5mU6QUPCRnHBKOacVnJK7VeuDt6Yt-oQZw2AGH8Oy6EwwT9hNwbIwwRW9GTax32yzj2182haxKQKOKc65t4Uf7OYTOW5Mm_HzoS7In58_fq9-lfcPN7er6_vSCiWHkivHxVphbdHYdaUUGCebxjDFKK6BOuOUwqbhYGvHlKA1rytQVNJGSImKL8jlfm-f4suIedCdzxbb1gSMY9aM1gIYo3JGL_5Dn-OYwvTdTAEwKSYRCyL3lE0x54SN7pPvTNpqoHqWrXey9WxSg9I72VpOc-eH7eO6Q_c29c_uBHzfAzjp-Osx6Ww9BovOJ7SDdtG_c-IVIUqNwA</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Steinhoff, Martin</creator><creator>Schmelz, Martin</creator><creator>Szabó, Imre Lőrinc</creator><creator>Oaklander, Anne Louise</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180801</creationdate><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><author>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Dermatology</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathy</topic><topic>Diagnosis</topic><topic>Disease Management</topic><topic>Drugs</topic><topic>Gastrin</topic><topic>Herpes zoster</topic><topic>Humans</topic><topic>Multiple sclerosis</topic><topic>Mutation</topic><topic>Narcotics</topic><topic>Nervous system</topic><topic>Neuralgia - diagnosis</topic><topic>Neuralgia - physiopathology</topic><topic>Neuralgia - therapy</topic><topic>Neurokinin</topic><topic>Neurokinin NK1 receptors</topic><topic>Peripheral neuropathy</topic><topic>Polyneuropathy</topic><topic>Pruritus</topic><topic>Pruritus - diagnosis</topic><topic>Pruritus - physiopathology</topic><topic>Pruritus - therapy</topic><topic>Skin</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steinhoff, Martin</creatorcontrib><creatorcontrib>Schmelz, Martin</creatorcontrib><creatorcontrib>Szabó, Imre Lőrinc</creatorcontrib><creatorcontrib>Oaklander, Anne Louise</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steinhoff, Martin</au><au>Schmelz, Martin</au><au>Szabó, Imre Lőrinc</au><au>Oaklander, Anne Louise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical presentation, management, and pathophysiology of neuropathic itch</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>17</volume><issue>8</issue><spage>709</spage><epage>720</epage><pages>709-720</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><abstract>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30033061</pmid><doi>10.1016/S1474-4422(18)30217-5</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1474-4422 |
ispartof | Lancet neurology, 2018-08, Vol.17 (8), p.709-720 |
issn | 1474-4422 1474-4465 |
language | eng |
recordid | cdi_proquest_miscellaneous_2074122058 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Clinical trials Cytokines Dermatology Diabetes mellitus Diabetic neuropathy Diagnosis Disease Management Drugs Gastrin Herpes zoster Humans Multiple sclerosis Mutation Narcotics Nervous system Neuralgia - diagnosis Neuralgia - physiopathology Neuralgia - therapy Neurokinin Neurokinin NK1 receptors Peripheral neuropathy Polyneuropathy Pruritus Pruritus - diagnosis Pruritus - physiopathology Pruritus - therapy Skin Ulcers |
title | Clinical presentation, management, and pathophysiology of neuropathic itch |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A36%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20presentation,%20management,%20and%20pathophysiology%20of%20neuropathic%20itch&rft.jtitle=Lancet%20neurology&rft.au=Steinhoff,%20Martin&rft.date=2018-08-01&rft.volume=17&rft.issue=8&rft.spage=709&rft.epage=720&rft.pages=709-720&rft.issn=1474-4422&rft.eissn=1474-4465&rft_id=info:doi/10.1016/S1474-4422(18)30217-5&rft_dat=%3Cproquest_cross%3E2071125403%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2071125403&rft_id=info:pmid/30033061&rft_els_id=S1474442218302175&rfr_iscdi=true |